Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse

Simple Summary Treatment for metastatic melanoma patients has significantly improved in the last decade. Literature suggests a better prognosis for patients with minimal disease burden. No consensus exists on the surveillance of melanoma patients at high risk of recurrence. In this trial we evaluated the use of whole-body MRI for the surveillance of melanoma patients, more specifically in patients with stage IIIb/c disease following surgical resection and in patients obtaining a durable response on systemic therapy. Overall, we can conclude that whole- body MRI is a safe and sensitive technique for the discovery of distant melanoma metastasis. Introduction: No standard protocol for surveillance for melanoma patients is established. Whole-body magnetic resonance imaging (whole-body MRI) is a safe and sensitive technique that avoids exposure to X-rays and contrast agents. This prospective study explores the use of whole-body MRI for the early detection of recurrences. Material and Methods: Patients with American Joint Committee on Cancer Staging Manual (seventh edition; AJCC-7) stages IIIb/c or -IV melanoma who were disease-free following resection of macrometastases (cohort A), or obtained a durable complete response (CR) or partial response (PR) following systemic therapy (cohort B), were included. All patients underwent whole-body MRI, including T1, Short Tau Inversion Recovery, and diffusion-weighted imaging, every 4 months the first 3 years of follow-up and every 6 months in the following 2 years. A total body skin examination was performed every 6 months. Results: From November 2014 to November 2019, 111 patients were included (four screen failures, cohort A: 68 patients; cohort B: 39 patients). The median follow-up was 32 months. Twenty-six patients were diagnosed with suspected lesions. Of these, 15 patients were diagnosed with a recurrence on MRI. Eleven suspected lesions were considered to be of non-neoplastic origin. In addition, nine patients detected a solitary subcutaneous metastasis during self-examination, and two patients presented in between MRIs with recurrences. The overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were, respectively, 58%, 98%, 58%, 98%, and 98%. Sensitivity and specificity for the detection of distant metastases was respectively 88% and 98%. No patient experienced a clinically meaningful (>grade 1) adverse event. Conclusions: Whole-body MRI for the surveillance of melanoma patients is a safe and sensitive technique sparing patients ' cumulative exposure to X-rays and contrast media.

Automated summary

Treatment for metastatic melanoma patients has significantly improved in the last decade. Whole-body MRI is a safe and sensitive technique for surveillance, allowing for the early detection of distant metastases in melanoma patients.